“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

The primary objective of this report is to describe the safety of long-term use of EryDex in treatment of pediatric patients with ataxia telangiectasia. Methods: This is a post-hoc analysis of ...

Back to Healio Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age ...

• In a large cohort of AT patients (n = 65), we observed reduced levels of B cells, CD4 + cells, and CD8 + T cells and no difference in the amount of NK and NKT cells in peripheral blood compared with ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...